| Today’s Big NewsAug 9, 2023 |
| By Gabrielle Masson Nektar Therapeutics CEO Howard Robin is not backing down after the biotech accused Eli Lilly of botching the math behind the formerly partnered immunology asset rezpeg. |
|
|
|
By Conor Hale After accusing Guardant Health and its founders of absconding with company secrets more than 10 years ago, Illumina has opted to drop its lawsuit in favor of a new commercial partnership deal. |
By Fraiser Kansteiner AstraZeneca and Stratkraft—Europe’s largest renewable energy producer—have entered into an agreement on wind power deliveries that will increase the supply of renewable electricity in Sweden based on the commissioning of new wind farms |
By Kevin Dunleavy After striking out in the pandemic phase of COVID-19 with its belated vaccine, Novavax seeks to recover in the endemic phase. And a big part of the company's plan centers around enhancing its partnership with SK Bioscience. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
By Nick Paul Taylor Terns Pharmaceuticals has confirmed what other biotechs have already shown: selective activation of thyroid receptor-beta appears to reduce liver fat in non-alcoholic steatohepatitis. But with Terns years behind its rivals, the phase 2a trial failed to clear up doubts about whether TERN-501 can stand out. |
By Gabrielle Masson Part of EQRx’s implosion earlier this year included cutting ties with China-based Lynk Pharmaceuticals. However, Lynk seems to have safely removed itself from EQRx’s wreckage, as its eczema asset improved area and severity in a phase 2 clinical trial. |
By Andrea Park Kim Kardashian took to Instagram on Tuesday to boost the (already high) profile of scanning service provider Prenuvo. |
By Fraiser Kansteiner Despite a return to revenue growth in 2023’s second quarter, troubled Mallinckrodt continues to weigh its financial options, according to CEO Siggi Olafsson. Among them is a new bankruptcy bid that could get the company off the hook for more than $1 billion in opioid settlement payments. |
By Conor Hale Glympse Bio, developer of an injectable diagnostic platform, has been acquired by Sunbird Bio, which plans to point the companies’ resources toward a new blood test for Alzheimer’s disease. |
By James Waldron Takeda and Denali Therapeutics have made the joint decision to end work on their troubled Alzheimer’s disease therapy after a glimpse at early phase 1 data suggested it would get limited uptake by patients. |
By Andrea Park Boston Scientific is giving new meaning to the polar plunge. |
By Zoey Becker The company expects to announce three divestures this year, with one coming in the current quarter. After that, Viatris believes it can move into phase 2 of its return to growth strategy, which includes building out its growing eye care business. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
